P
PureTech Health plc D
D
PRTC
16.990
USD
0.49
(2.97%)
Market Closed
Volume
10
EPS
-5
Div Yield
-
P/E
10
Market Cap
410,621,184
Title: PureTech Health plc
Sector: Healthcare
Industry: Biotechnology
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, whichderives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.